Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans
Heather Eng, Alyssa Dantonio, Eugene P. Kadar, R. Scott Obach, Li Di, Jian Lin, Nandini C. Patel, Britton Boras, Gregory S. Walker, Jonathan J. Novak, Emi Kimoto, Ravi Shankar Prasad Singh, Amit S. Kalgutkar
Topics & Concepts
MicrosomeBioavailabilityCYP3A4PharmacologyPharmacokineticsOral administrationMetabolismProtease inhibitor (pharmacology)Drug metabolismFree fractionCytochrome P450RitonavirExcretionBiologyChemistryInternal medicineEndocrinologyMedicineEnzymeImmunologyBiochemistryDrugVirusViral loadAntiretroviral therapySARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsDrug-Induced Hepatotoxicity and Protection